Form 4 for NBIX NEUROCRINE BIOSCIENCES INC
Accepted 2026-05-21 17:49:51 ET · period of report 2026-05-19 · accession 0001201096-26-000010 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-05-21 17:49 | 2026-05-19 | NBIX | GORMAN KEVIN CHARLES | Dir | M - OptEx | $43.24 | +205.1K | 756.4K | +37% | +$8.87M |
| DT | 2026-05-21 17:49 | 2026-05-19 | NBIX | GORMAN KEVIN CHARLES | Dir | S - Sale+OE | $154.33 | -245.1K | 511.3K | -32% | -$37.82M |
| DT | 2026-05-21 17:49 | 2026-05-19 | NBIX | GORMAN KEVIN CHARLES | Dir | M - OptEx | $0.00 | -205.1K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-05-19 | M | A | 205,088 | $43.24 | 756,381 | D | — | — | |
| 2 | Common | Common Stock | 2026-05-19 | S | D | 245,088 | $154.33 | 511,293 | D | — | — | (F1) The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on February 17, 2026. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. (F2) Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $153.30 to $156.59. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. (F3) 511,293 of the outstanding shares are held by the Gorman and Blais Family Trust, of which Dr. Gorman has voting and investment power. |
| 3 | Derivative | Non-Qualified Stock Option | 2026-05-19 | M | D | 205,088 | $0.00 | 0 | D | $43.24 · — to 2027-02-06 | 205,088 Common Stock | (F4) The option was granted February 6, 2017 and vested in 48 equal monthly installments beginning March 6, 2017. These options were due to expire on February 6, 2027. |